EP2063898A4 - Utilisation d'équol pour améliorer ou prévenir des maladies ou des troubles neuropsychiatriques et neurodégénératifs - Google Patents

Utilisation d'équol pour améliorer ou prévenir des maladies ou des troubles neuropsychiatriques et neurodégénératifs

Info

Publication number
EP2063898A4
EP2063898A4 EP06813546A EP06813546A EP2063898A4 EP 2063898 A4 EP2063898 A4 EP 2063898A4 EP 06813546 A EP06813546 A EP 06813546A EP 06813546 A EP06813546 A EP 06813546A EP 2063898 A4 EP2063898 A4 EP 2063898A4
Authority
EP
European Patent Office
Prior art keywords
equol
ameliorating
disorders
neurodegenerative diseases
preventing neuropsychiatric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06813546A
Other languages
German (de)
English (en)
Other versions
EP2063898A1 (fr
Inventor
Edwin Douglas Lephart
Trent D Lund
Kenneth David Reginald Setchell
Robert J Handa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cincinnati Childrens Hospital Medical Center
Brigham Young University
Colorado State University Research Foundation
Colorado State University
Original Assignee
Cincinnati Childrens Hospital Medical Center
Brigham Young University
Colorado State University Research Foundation
Colorado State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cincinnati Childrens Hospital Medical Center, Brigham Young University, Colorado State University Research Foundation, Colorado State University filed Critical Cincinnati Childrens Hospital Medical Center
Publication of EP2063898A1 publication Critical patent/EP2063898A1/fr
Publication of EP2063898A4 publication Critical patent/EP2063898A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)
EP06813546A 2006-08-18 2006-08-18 Utilisation d'équol pour améliorer ou prévenir des maladies ou des troubles neuropsychiatriques et neurodégénératifs Withdrawn EP2063898A4 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2006/032387 WO2008020853A1 (fr) 2006-08-18 2006-08-18 Utilisation d'équol pour améliorer ou prévenir des maladies ou des troubles neuropsychiatriques et neurodégénératifs

Publications (2)

Publication Number Publication Date
EP2063898A1 EP2063898A1 (fr) 2009-06-03
EP2063898A4 true EP2063898A4 (fr) 2012-02-15

Family

ID=39082297

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06813546A Withdrawn EP2063898A4 (fr) 2006-08-18 2006-08-18 Utilisation d'équol pour améliorer ou prévenir des maladies ou des troubles neuropsychiatriques et neurodégénératifs

Country Status (5)

Country Link
EP (1) EP2063898A4 (fr)
JP (1) JP2010501485A (fr)
AU (1) AU2006347276B2 (fr)
CA (1) CA2660056A1 (fr)
WO (1) WO2008020853A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2607109C2 (ru) * 2011-04-20 2017-01-10 Нестек С.А. Способы и композиции, пригодные для предотвращения и лечения гиперлептинемии
KR101553292B1 (ko) 2013-11-06 2015-09-17 한국식품연구원 후각과민증 예방 또는 치료용 조성물
KR20160026042A (ko) * 2014-08-29 2016-03-09 (주)아모레퍼시픽 락토비온산을 함유하는 항스트레스용 또는 항상성 유지용 조성물
EP3490551A2 (fr) * 2016-07-26 2019-06-05 Ausio Pharmaceuticals, LLC Méthodes de diagnostic et de traitement de la maladie d'alzheimer par s-équol

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004039327A2 (fr) * 2002-10-29 2004-05-13 Colorado State University Research Foundation Utilisation d'equol dans le traitement de maladies d'origine androgenique

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5733926A (en) * 1996-12-13 1998-03-31 Gorbach; Sherwood L. Isoflavonoids for treatment and prevention of alzheimer dementia and reduced cognitive functions
US6083526A (en) 1997-05-22 2000-07-04 Gorbach; Sherwood L. Use of isoflavonoids in the treatment or prevention of postpartum depression
GB0224506D0 (en) 2002-10-22 2002-11-27 Medical House The Plc Needless injection device
CA2564399A1 (fr) 2004-04-28 2005-11-17 Brigham Young University Utilisation de l'equol dans le traitement des maladies de la peau

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004039327A2 (fr) * 2002-10-29 2004-05-13 Colorado State University Research Foundation Utilisation d'equol dans le traitement de maladies d'origine androgenique

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LEPHART E D ET AL: "Behavioral Effects of Endocrine-disrupting Substances: Phytoestrogens", ILAR JOURNAL, INSTITUTE FOR LABORATORY ANIMAL RESEARCH, US, vol. 45, no. 4, 1 January 2004 (2004-01-01), pages 443 - 454, XP003024366, ISSN: 1084-2020 *
See also references of WO2008020853A1 *

Also Published As

Publication number Publication date
AU2006347276A1 (en) 2008-02-21
WO2008020853A1 (fr) 2008-02-21
CA2660056A1 (fr) 2008-02-21
AU2006347276B2 (en) 2012-11-29
JP2010501485A (ja) 2010-01-21
EP2063898A1 (fr) 2009-06-03

Similar Documents

Publication Publication Date Title
EP2010187A4 (fr) Composés pour le traitement de maladies et de troubles
EP2034839A4 (fr) Traitement de maladies neurodégénératives par l'inhibition de hsp90
EP2166837A4 (fr) Combinaison médicamenteuse utilisable pour le traitement de troubles cutanés
EP1981526A4 (fr) L'adiponectine pour le traitement de divers troubles
EP2152865A4 (fr) Méthodes de traitement et de prévention de maladies et de troubles neurodégénératifs
HK1166983A1 (zh) 包含用於治療疾病或紊亂的化合物的固體形式，其組合物，及其用途
GB0610350D0 (en) prevention and/or treatment of neuodegenerative disorders
EP2004204A4 (fr) Traitement de maladies neurodegénératives
ZA200901523B (en) Use of extracts for the treatment of viral disorders
IL190652A0 (en) Novel pharmaceutical combinations for the treatment of respiratory disorders
EP1928468A4 (fr) Therapie par estriol pour maladies et troubles neurodegeneratifs et autoimmuns
IL201449A0 (en) Heteroarylamide-substituted pyrimidone derivatives for the treatment of neurodegenerative diseases
ZA200806455B (en) Use of 2-imidazoles for the treatment of CNS disorders
GB0610183D0 (en) Treatment of neurodegenerative diseases
GB0603181D0 (en) Treatment of neurodegenerative and psychiatric diseases
HK1121378A1 (en) Compositions and methods for the treatment of addiction and other neuropsychiatric disorders
EP2077838A4 (fr) Procedes pour le traitement de troubles en rapport avec a , et compositions pour ceux-ci
IL193799A0 (en) New therapeutic combinations for the treatment or prevention of psycotic disorders
GB0714447D0 (en) Cannabidiol for use in the treatment of neurodegenerative conditions
EP2063898A4 (fr) Utilisation d'équol pour améliorer ou prévenir des maladies ou des troubles neuropsychiatriques et neurodégénératifs
IL198134A (en) A combination of antipsychotic drugs and tetracyclines to treat psychiatric illnesses
IL192877A0 (en) Use of 2-imidazoles for the treatment of cns disorders
ZA200805108B (en) Treatment of neurodegenerative disorders
ZA200802270B (en) Treatment of neurodegenerative disorders
ZA200901094B (en) Methods and tools for the therapy of neurodegenerative pathologies

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090316

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

RIN1 Information on inventor provided before grant (corrected)

Inventor name: HANDA, ROBERT, J.

Inventor name: SETCHELL, KENNETH, DAVID REGINALD

Inventor name: LUND, TRENT, D.

Inventor name: LEPHART, EDWIN, DOUGLAS

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

A4 Supplementary search report drawn up and despatched

Effective date: 20120117

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/56 20060101AFI20120111BHEP

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120814